Language selection

Search

Patent 2396229 Summary

Third-party information liability

Some of the information on this Web page has been provided by external sources. The Government of Canada is not responsible for the accuracy, reliability or currency of the information supplied by external sources. Users wishing to rely upon this information should consult directly with the source of the information. Content provided by external sources is not subject to official languages, privacy and accessibility requirements.

Claims and Abstract availability

Any discrepancies in the text and image of the Claims and Abstract are due to differing posting times. Text of the Claims and Abstract are posted:

  • At the time the application is open to public inspection;
  • At the time of issue of the patent (grant).
(12) Patent: (11) CA 2396229
(54) English Title: COMPLIANT POLYMERIC MATERIALS FORMED FROM MACROMERS
(54) French Title: MATERIAUX POLYMERIQUES COMPLIANTS FORMES A PARTIR DE MACROMERES
Status: Expired
Bibliographic Data
(51) International Patent Classification (IPC):
  • C08G 64/00 (2006.01)
  • C08G 65/00 (2006.01)
(72) Inventors :
  • JARRETT, PETER K. (United States of America)
  • SAWHNEY, AMARPREET (United States of America)
  • COURY, ARTHUR J. (United States of America)
  • RUDOWSKY, RONALD S. (United States of America)
  • POWELL, MICHELLE D. (United States of America)
  • AVILA, LUIS Z. (United States of America)
  • ENSCORE, DAVID J. (United States of America)
  • GOODRICH, STEPHEN D. (United States of America)
  • NASON, WILLIAM C. (United States of America)
  • YAO, FEI (United States of America)
  • WEAVER, DOUGLAS (United States of America)
  • BARMAN, SHIKHA P. (United States of America)
(73) Owners :
  • GENZYME CORPORATION (United States of America)
(71) Applicants :
  • FOCAL, INC. (United States of America)
(74) Agent: BERESKIN & PARR LLP/S.E.N.C.R.L.,S.R.L.
(74) Associate agent:
(45) Issued: 2006-05-30
(22) Filed Date: 1997-09-23
(41) Open to Public Inspection: 1998-03-26
Examination requested: 2002-08-22
Availability of licence: N/A
(25) Language of filing: English

Patent Cooperation Treaty (PCT): No

(30) Application Priority Data:
Application No. Country/Territory Date
710,689 United States of America 1996-09-23
60/054,849 United States of America 1997-08-06

Abstracts

English Abstract

Water-soluble macromers including at least one hydrolysable linkage formed from carbonate or dioxanone groups, at least one water-soluble polymeric block, and at least one polymerizable group, and methods of preparation and use thereof are described. The macromers are preferably polymerized using free radical initiators under the influence of long wavelength ultraviolet light or visible light excitation. Biodegradation occurs at the linkages within the extension oligomers and results in fragments which are non-toxic and easily removed from the body. The macromers can be used to encapsulate cells, deliver prophylactic, therapeutic or diagnostic agents in a controlled manner, plug leaks in tissue, prevent adhesion formation after surgical procedures, temporarily protect or separate tissue surfaces, and adhere or seal tissues together.


French Abstract

Macromères hydrosolubles comprenant au moins un lien hydrolysable formé à partir de groupes de carbonate ou de dioxanone, au moins un bloc de polymère hydrosoluble et au moins un groupe polymérisable, et modes de préparation et d'utilisation connexes. Les macromères sont préférablement polymérisées à l'aide d'initiateurs de radicaux libres sous l'influence d'une lumière ultraviolette de grande longueur d'ondes ou de l'exposition à une source lumineuse. La biodégradation se produit aux liaisons dans les oligomères et crée des fragments non toxiques qui peuvent facilement être retirés du corps. Les macromères peuvent être utilisées pour encapsuler des cellules, fournir des agents prophylactiques, thérapeutiques ou diagnostiques de manière contrôlée, colmater les fuites des tissus, empêcher la formation d'adhérences après les chirurgies, protéger ou séparer temporairement la surface des tissus et assurer l'adhésion ou le scellage des tissus.

Claims

Note: Claims are shown in the official language in which they were submitted.





50

CLAIMS

1. A compliant polymeric material, wherein the material is formed by the
polymerization of an aqueous solution or suspension of a polymerizable
macromer in
contact with a surface,
wherein the macromer comprises at least one water-soluble region, at least one
biodegradable region, and at least one reactive polymerizable group or region
capable
of crosslinking with other macromers,
wherein the polymerizable regions are separated from each other by at least
one biodegradable region,
wherein at least one biodegradable region comprises a carbonate or dioxanone
linkage, and
wherein the normalized compliance ratio of the surface and the material is in
the range of about 0.05 to about 3.

2. The material of claim 1 wherein the material is a hydrogel, wherein the
polymerizable groups are photopolymerizable groups, and wherein the macromer
is
polymerized in the presence of a free radical polymerization initiator.

3. The material of claim 1 wherein the surface is the surface of tissue and
the
material has an elongation at rupture which is similar or greater than the
elongation of
the tissue in vivo.

4. The material of claim 1 wherein the material has an elongation at rupture
which is greater than about 100%.

5. The material of claim 1 wherein the material has an elastic modulus which
is
less than about 150 kPa.

6. The material of claim 1wherein the material has an adherence to the surface
of
at least about 20 grams per square centimeter.




51


7. The material of claim 1 wherein the material further comprises a
biologically
active material.
8. The material of claim 1 wherein the material is biodegradable.
9. The material of claim 1 wherein the material is a sealant on a tissue
surface.
10. The material of claim 1 wherein the material adheres two surfaces
together,
and wherein at least one of the surfaces is a tissue surface.
11. The material of claim 10 wherein the second surface is selected from the
group consisting of surfaces of medical devices, implants, and wound
dressings.
12. The material of claim 1 wherein the material is a coating on a surface.
13. The material of claim 12 wherein the surface is selected from the group
consisting of surfaces of drug delivery devices, cells, tissues, and implants.
14. The material of claim 13 wherein the surface is a tissue surface selected
from
the group consisting of vascular tissue, nerves, cornea, cochlea, lung, liver,
kidney,
and spleen.
15. The material of claim 7 wherein the biologically active material is
selected
from the group consisting of therapeutic, prophylactic and diagnostic agents.
16. The material of claim 15 wherein the biologically active material is
releasable
from the material in a controlled manner.
17. The material of claim 16 wherein the biologically active material is in an
amount effective to treat a localized medical condition.

Description

Note: Descriptions are shown in the official language in which they were submitted.



CA 02396229 2003-O1-31
1
COMPLIANT POLYMERIC MATERIALS
FORMED FROM MACROMERS
Field of the invention
The present invention relates to improved photopolymerizable
biodegradable hydrogeIs for use as tissue adhesives, coatings, sealants and
in controlled drug delivery devices. The improved materials incorporate
carbonate andlor dioxanone linkages. These biodegradable linkages allow
improved control of various properties of the macromers, particularly
increasing viscosity while preserving biodegradability.
Baclcgronnd of the Invention
U.S. Patent No. 5,410,016 to Hubbell et al. discloses
biocompatible, biodegradable macromers which can be polymerized to
form hydrogels. The macromers are block copolymers that include a
biodegradable block, a water-soluble block with sufficient hydrophilic
character to make the macromer water-soluble, and one or more
polymerizabie groups. The polymerizable groups are separated from each
other by at least one degradable group, Hubbell specifically discloses using
polyhydroxy acids, such as polylactide, polyglycolide and polycapmlactone
as the biodegradable polymeric blocks. One of the disclosed uses for the
macromers is to plug or seal leaks in tissue.
Other hydrogels have been described, for example, in U.S. Patent
No. 4,938,763 to Dunn et al., U.S. Patent Nos. 5,100,992 and 4,826,945 to
Cohn ct al., U.S. Patent Nos. 4,741,872 and 5,160,745 to De Luca et al.,
U.S. Patent No. 5,527,864 to Suggs et al., and U.S. Patent No. 4,511,478
to Nowinski et al. Methods of using such polymers are described in U.S.
Patent No. 5,573,934 to Hubbell et al. and PCT WO 96/29370 by Focal.
While numerous references disclose using homopolymers and
copolymers including carbonate linkages to form solid medical devices,
such as sutures, suture coatings and drug delivery devices (see, for
example, U.S. Patent No. 3,301,824 to Hostettler et al., U.S. Patent No.
4,243,775 to Rosensaft et al., U.S. Patent No. 4,429,080 to Casey et al.,


CA 02396229 2003-O1-31
2
U.S. Patent No. 4,716,20 to Casey et al., U.S. Patent No. 4,857,602 to
Casey et al., U.S. Patent No. 4,882,168 to Casey, EP 0 390 860 Bl by
Boyle et al., U.S. Patent No. 5,066,772 to Tang et al., U.S. Patent No.
5,366,756 to ChesterFeld et al., U.S. Patent No. 5,403,347 to Roby et al.
5 and U.S. Patent No. 5,522,841 to Roby et al.), none of these publications
discloses incorporating polymerizable groups on the polymers so that the
polymers can be further polymerized. Accordingly, none of these
polymers can be used in the same manner as the macromers in U.S. Patent
No. 5,410,016 to Hubbell et al.
10 Sealing or plugging holes in lung tissue is inherently more difficult
than sealing other types of tissue because the tissue is constantly expaaded
and contracted during normal respiration. It would be advantageous to
provide macromers which can be rapidly polymerized in vivo to form
hydrogels which are more elastic than conventional hydrogels, for
15 example, for use in sealing lung tissue.
It is therefore an object of the present invention to pmvide
biodegradable, biocompatible macromers that can be rapidly polymerized
in vivo to form hydrogels which are more elastic than conventional
hydrogels.
20 ' It is a further object of the present invention to provide a macromcr
solution which can be administered during surgery or outpatient procedures
and polymerized as a tissue adhesive, cell encapsulating medium, tissue
sealant, wound dressing or drug delivery device.
It is a still further object of the present invention to provide a
25 macromer solution which can be polymerized in vivo on a surface to be
coated in a very short time frame to form conformal coating layers.
Summary of the Invention
Biocompadble, biodegradable, polymerizable and at least
substantially water-soluble macromers and methods of preparation and use
30 thereof are disclosed.


CA 02396229 2003-O1-31
2a
The present invention relates to compliant polymeric materials which are
formed
from macromers. More specifically, the present invention provides a compliant
polymeric material, wherein the material is formed by the polymerization of an
aqueous
solution or suspension of a polymerizable macromer in contact with a surface,
wherein
the macromer comprises at least one water-soluble region, at least one
biodegradable
region, and at least one reactive polymerizable group or region capable of
crosslinking
with other macromers, wherein the polymerizable regions are separated from
each other
by at least one biodegradable region, wherein at least one biodegradable
region comprises
a carbonate or dioxanone linkage, and wherein the normalized compliance ratio
of the
tissue and the material is in the range of about 0.05 to about 3.
The macromers disclosed herein are block copolymers that include at least one
water-soluble block, at least one biodegradable block, and at least


CA 02396229 2002-08-22
' ' 3
one polymerizable gmup. At least one of the biodegradable blocks
comprises a linkage based on a carbonate or dioxanone group, and the
macromers can contain other degradable linkages or groups in addition to
carbonate or dioxanone.
The carbonate and dioxanone linkages impart more elasticity to the
polymer and degrade at a different rate than hydroxy acid linkages.
Carbonate linkages can also increase macromer viscosity, at a given
concentration, without requiring increased molecular weight of the
nondegradable components of the macromer. The macromers can also
include poly(hydroxy acid) linkages which degrade by hydrolysis into
relatively non-toxic hydroxy acid residues, or other biodegradable blocks
such as polycaprolactones, polyorthoesters, polyanhydrides, and
polypeptides. The degradation time of the polymers can be controlled, for
example, by selecting the types and proportion of the biodegradable
blocks.
The polymerizable groups can be polymerized by either free radical
(hemolytic) processes or by heterolytic processes (such as cationic
polymerization). Preferably, the groups are polymerized photochemically.
The macromer can be polymerized in the presence of prophylactic,
therapeutic or diagnostic agents, for delivery of the incorporated agents in
a controlled manner as the resulting polymer degrades. The macromers
are useful for delivering hydrophobic, hydrophilic and/or labile materials.
They can be particularly useful for delivery of hydrophobic materials.
The macromers can be polymerize in an interfacial manner to
form ultrathin coatings which are intimately adhered to the coated surface,
or in a bulls manner to form relatively thick coatings which may or tray
not be intimately adhered to the coated surface. Alternatively, the two
methods can be combined to provide a relatively thick coating which is
intimately adhered to the surface. Each of these methods is advantageous
for certain applications.


CA 02396229 2002-08-22
4
Brief Description of the Figures
Figure 1 is a graph of the elastic strength (seal pressure, mm Hg)
over time (hr) of five different sealant materials: 10% 35K T, 20% 35K
T, 10% 20K TL, 10% 20 K TL, and 20% 35K TL K is defined as 100
5 Daltons (weight average molecular weight, T is trimethylene carbonate
(TMC), L is lacdde, and TL is a copolymer of TMC and lactide.
Figures 2A and 2B arc graphs of the degradation (% mass loss)
over time (days) for 20K T (Figure 2A) and 35K T (Figure 2B) for
subcutaneous polymeric implants in rats.
10 Figure 3 shows the stress vs. strain curve of a compliant sealant
formed by photopolymerization of a polyethylene glycol
oligotrimethylene carbonate copolymer end capped with acrylate ester.
Detailed Description of the Invention
15 As used herein, the term "sealant" refers to a material which
decreases or prevents the migration of fluid from or into a surface such as
a tissue surface. Sealants are typically formed by the application of
precursor molecules to a tissue followed by local polymerization. The
same materials may also be used to adhere materials together, either when
20 applied between them and polymerized, or when used to jointly embed
materials.
As used herein, the term "biocompatibility," in the context of
biologically-related uses, refers to the absence of stimulation of a severe,
long-lived or escalating biological response to an implant or coating, and
25 is distinguished from a mild, transient inflammation which typically
accompanies surgery or implantation of foreign objects into a living
organism.
As used herein the term "biodegradability" refers to the
disintegration, which is preferably predictable, of an implant into small


CA 02396229 2002-08-22
5
entities which will be metabolized or excreted, under the conditions
normally present in a living tissue.
The properties of the particular coating or barrier materials
disclosed herein are referred to as "materials properties", and include:
5 the "Young's modules" (of elasticity) which is the limiting modules
of elasticity extrapolated to zero strain;
the "elastic modules" which is any modules of elasticity, not
limited to Young's modules, and may include "secant modules" and other
descriptors of non-linear regions of the stress-strain curve;
10 the "bulk" or "compressive" modules which is used in its usual
sense of ratio of stress to a designated compressive strain;
the "elongation at failure" which is the relative strain or extension
of a test specimen at which any irreversible or hysteresis-inducing change
occurs in the specimen; and
15 the "elongation at break" or "elongation at rupture" which is the
relative strain (extension) of a test specimen at which mechanical rupture
occurs.
The term "compliance" as used herein is used in a general sense,
and refers for example to the ability of an implant to closely match the
20 physiological and mechanical properties of tissues at the implant site,
except when "compliance" is used in a specific technical sense as the
reciprocal of a modules.
As applied to a relatively thin, flat material such as a tissue or a
layer of sealant, "normalized compliance" (NC) is defined herein as the
25 strain,(i.e., the elongation or compression per unit length of a specimen),
divided by the applied force per unit cross-sectional area, further divided
by the thickness of the specimen. Hence, for a sample having a width w
(for example, the width of the clamps of the testing ap~ratus), and a
thickness t, when an applied force F produces a strain S, then the
30 compliance C is


CA 02396229 2002-08-22
' ' 6
C= S -
F/wt F
and the normalized compliance is
NC= C - ~ = Sew
t F/w F
i. e. , the strain in the sample divided by the force per unit width applied
to
the sample. The normalized compliance allows direct comparison of the
farces required to deform the tissue versus a coating on the tissue, without
regard to the relative thicknesses of these materials.
The normalized compliance ratio (abbreviated NCR) is defined as
the value of the normalized compliance of the tissue or other substrate
divided by the normalized compliance of the sealant material. When both
measurements are conducted on strips of the same width and at the same
force, the NCR is simply the ratio of the strains at a particular force. A
low NCR (less than 1 ) is obtained when the sealant material is easier to
deform than the tissue, while a high NCR (greater than 1 ) is obtained
when the tissue is easier to deform than the sealing material.
As used herein, the term "elastomer" refers to a polymeric material
which at room temperature is capable of repeatedly recovering in size and
shape after removal of a deforming force. In some embodiments, an
elastomer is a material which can be repeatedly stretched to twice its
original length and will repeatedly return to its approximate length on
release of the stress.
The phrase "elastomeric materials" is a phrase which has been used
in the literattn~e. There are many publications describing structure-
property relationships of elastomers and other deformable materials.
Lower elastic modulus and, frequently, an increased reversible elongation
to break or fracture, are found when any of the following occur:
1. The distance between nodes or junctions or more crystalline
("hard") segments increases.


CA 02396229 2002-08-22
7
2. The crosslink density decreases. This may be controlled by
amount of crosslinker, nature of crosslinker, and degree of cure, as well as
by segment length of either the crosslinked species or the crosslinking
species, where different.
5 3. For a material at equilibrium with a continuous phase, an
increase in the plasticization of the elastomer by the continuous phase.
For applications wherein the continuous phase is water, more particularly
physiological saline, increasing hydrophilicity tends to increase
compliance.
10 In order to seal fluid leaks in tissue, the sealing material must
remain firmly bonded to the tissue during motions required of the tissue
during the healing process. For tissues and organs which cannot be
immobilized, such as the lung, an effective sealing material is both tightly-
adherent and compliant, having materials properties similar to those of the
15 tissue. Examples of compliant adherent materials and methods for their
construction and use are provided.
In one embodiment, one or more initiators are applied to a surface
to form an absorbed layer. "Absorbed" is used herein to encompass both
"absorbed" and "adsorbed". A solution of polymetizable molecules,
20 referred to herein as "monomers", is then applied.
a s
In one embodiment, one or more initiators or components of an
initiation system are applied directly to the surface, and the unabsorbed
25 excess is optionally removed by washing or blotting. The initiator solution
may further contain one or more polymerizable monomers, and other
useful formulating ingredients, including accelerators, co-initiators,
sensitizers, and co-monomers. Then a liquid containing polymerizable
monomers in combination with one or more initiators or components of an
30 initiation system, which may be the same as or different from that
absorbed in the first step, is applied. The system, if not self polymerizing,


CA 02396229 2002-08-22
is then stimulated to polymerize, for example by application of an
appropriate wavelength of light.
The priming and monomer-application slaps can also be combined.
For example, if excess initiator is not removed before monomer addition,
then subsequent application of monomer will result in mixture of initiator
into the monomer layer. Similarly, if the monomer layer contains an
initiator with a high amity for the surface, then it is possible to apply a
monomer layer containi~~g initiator, and wait an appropriate time to allow
preferential absorption of the initiator to the surface, to achieve the same
effect.
All of these methods may collectively be described as application
of the monomer in an "initiating-incorporating manner", encompassing any
means of application and mixing which results in both an absorbed layer
of initiator, and a layer of monomer incorporating an initiator, being
present on a surface to 1x coated.
The initiators may be chemical, photochemical, or a combination
thereof. With non-photochemical systems, a r~uctant component and an
oxidant component may be present in the two parts of the solution, i.e., in
the priming layer and the coating layer.
Alternatively, a two-step process can be used to form polymers,
especially bioabsorbable hydrogels on tissue. In the first step the tissue is
treated with an initiator or a part of an initiator system for the
polymerization of olefinic (e.g. acrylic) or other functional monomers,
optionally with monomer in the priming solution. This provides an
activated tissue surface. In the second step, monomers) and, if
appropriate, the remainder of an initiator system, are together placed in
contact with the activated tissue, resulting in polymerization on the tissue.
An example of such a system is the combination of a peroxygen
compound in one part, and a reactive ion, such as a transition metal, in
another.


CA 02396229 2002-08-22
9
This process of spontaneous polymerization does not require the
use of a separate energy source. Moreover, since the process of
polymerization is initiated when part one contacts part two, there are no
"pot life" issues due to initiation of polymerizatioa If desired, part one or
5 part two can contain dyes or other means for visualizing the hydrogeI
coating.
An example of a system that can be used in this method is the
spontaneous "contact" initiator systems such as those found in two part
"acrylic structural adhesives". All components of the materials used as
10 described herein, however, must display biocompatibility as well as the
ability to spontaneously polymerize on tissue. The use of tributyl borane
for this purpose is illustrated here.
These systems can markedly simplify the delivery of gel to tissue,
especially in areas hard to reach or hold for a photochemical system. The
15 delivery system can be much simpler. Moreover, it has been discovered
that a two-part chemical system such as a ralox system and especially one
based on peroxygen, can be used to chemically enhance the curing of a
photochemical system, thereby combining the control of a photochemical
system with the ability of a chemical system to overcome colored
20 impurities, such as blood.
Po m
Water-soluble, biocompatible, biodegradable macromers and
methods of preparation and use thereof, are disclosed. The macromers
25 include at least one water-soluble block, at least one biodegradable block,
and at least one polymerizable group. At least one biodegradable block
contains a carbonate or dioxanone group. To obtain a biodegradable
material after polymerization, each polymerizable group must be separated
from any other polymerizable group on the macromer by at least one
30 biodegradable linkage or group.
At least a portion of the macromers will contain more than one
reactive group and thereby be effective as crosslinkers, so that the


CA 02396229 2002-08-22
10
macromers can be crossfmked to form a gel. The minimal proportion
required will vary with the nature of the macromer and its concentration in
solution, and the proportion of crosslinker in the macromer solution can be
as high as 100% of the macmmer solution.
5 For example, the macromers iaclude at least 1.02 polymerizable
groups on average, and, more preferably, the macromers each include two
or more polymerizable groups on average.
Since in the preferred homolytic (free radical) polymerization
reactions each polymerizable group will polymerize into a chain,
10 crosslinked hydrogels can be produced using only slightly more than one
reactive group per macromer (i.e., about 1.02 polymerizable groups on
average). However, higher percentages are preferable, and excellent gels
can be obtained in polymer mixtures in which most or all of the molecules
have two or more reactive double bonds. Poloxamines, an example of a
15 water-soluble block, have four arms and thus may readily be modified to
include four polymeriZable groups.
As used herein, a "biocompatible" material is one which stimulates
only a mild, often transient, implantation response, as opposod to a severe
or escalating response.
20 As used herein, a "biodegradable" material is one which
decomposes under normal in vivo physiological conditions into
components which can be metabolized or excreted.
As used herein, a "block" is a region of a copolymer differing in
subunit composition from neighboring regions. Blocks will generally
25 contain multiple subunits, up to about one thousand subunits or less for
non-degradable materials, and without an upper limit for degradable
materials. In the lower limit, the size of a block depends on its function;
the minimum size is that which is sufficient to allow the function to be
performed. In the case of a block conferring water-solubility on the
30 macmmer, this will be typically 400 daltons or more, preferably 600
daltons or more, more preferably at least 1000 daltons, and most
preferably in the range of 2000 to 40,000 daltons. For degradable


CA 02396229 2002-08-22
I1
linkages, the minimum block size is a single linkage of the appropriate
degradability for the function. More preferably, the block size is two to
forty groups; most preferably, three to twenty. The reactive groups may
be considered as a block for some purposes; the typical number of units in
S such a block is one, but may be two to five.
As used herein, a carbonate is a functional group with the structure
-O-C(O)-O-. The carbonate starting material can be cyclic, such as
trimethylene carbonate (TMC), or can be linear, such as dimethylcarbonate
(CH30-C(O)-OCH3). After incorporation into the polymerizable
10 macromer, the carbonate will be present at least in part as
R-O-C(=O)-O-R', where R and R' are other components of the macromer.
As used herein, a dioxanone is a repeating unit with the structure
-O-C(O)-R-O-, where R is a straight, branched or cyclic alkyl group. An
example of a cyclic dioxanone is 1,4-dioxan-2-one. 1,4-dioxan-2-one is a
1 S preferred dioxanone.
As used herein, a hydmgel is a substance formed when an organic
polymer (natural or synthetic) is cross-linked via covalent, ionic, or
hydrogen bonds to create a three-dimensional open-lattice structure which
entraps water molecules to farm a gel.
20 As used herein, "water-soluble" is defined as a solubility of at least
one gram/liter in an aqueous solution at a temperature in the range of
about 0° C and 50°C. Aqueous solutions can include small amounts
of
water-soluble organic solvents, such as dimethylsulfoxide,
dimethylformamide, alcohols, acetone, and/or glytnes.
25 Types of Block Copolymers
In general terms, the macromers are block co-polymers that
comprise a biodegradable block, a water-soluble block, and at least one
polymerizable gmup. Preferably, the macromers comprise at least 1.02
polymerizable gmups on average, and, more preferably, include at least
30 two polymerizable groups per macromer, on average. Average numbers of
polymerizable groups can be obtained, for example, by blending
macromers with different amounts of polymerizable groups.


CA 02396229 2002-08-22
12
The individual polymeric blocks can be arranged to form different
types of block copolymers, including di-block, tri-block, and mufti-block
copolymers. The polymerizable blocks can be attached directly to
biodegradable blocks or indirectly via water-soluble nondegradable blocks,
5 and are preferably attached so that the polymerizable gmups are separated
from each other by a biodegradable block. For example, if the macromer
contains a water-soluble block coupled to a biodegradable block, one
polymerizable group may be attached to the water-soluble block and
another attached to the biodegradable block. Preferably, both
10 polymerizable groups would be linked to the water-soluble block by at
least one degradable linkage.
The di-block copolymers include a water-soluble block linked to a
biodegradable block, with one or both ends capped with a polymerizable
group. The tri-block copolymers can include a central water-soluble block
15 and outside biodegradable blocks, with one or both ends capped with a
polymerizable group. Alternatively, the central block can be a
biodegradable block, and the outer blocks can be water-soluble. The
multiblock copolymers can include one or more of the water-soluble
blocks and biocompatible blocks coupled together in a linear fashion.
20 Alternatively, the multiblock copolymers can be brush, comb, dendritic or
star copolymers. If the backbone is formed of a water-soluble block, at
least one of the branches or grafts attachod to the backbone is a
biodegradable block. Alternatively, if the backbone is foamed of a
. biodegradable block, at least o~ of the braes or grafts attached to the
25 backbone is a water-soluble block, unless the biodegradable block is also
water-soluble. In another embodiment, a multifunctional compound, such
as a polyol, can be coupled to multiple polymeric blocks, at least one of
which is water-soluble and at least one of which is biodegradable.
In general, any formulation of the macromer which is intended to
30 be biodegradable must be constructed so that each polymaiz8ble gmup is
separated from each other polymerizable group by one or more linkages


CA 02396229 2002-08-22
13
which are biodegradable. Non-biodegradable materials are not subject to
this constraint.
Those skilled in the art will recognize that the individual polymeric
blocks may have uniform compositions, or may have a range of molecular
5 weights, and may be combinations of relatively short chains or individual
species which confer specifically desired properties on the final hydrogel,
while retaining the required characteristics of the tnacromer. The lengths
of oligomers referred to herein may vary from single units (in the
biodegradable portions) to many, subject to the constraint of preserving the
10 overall water-solubility of the macromer.
In the discussion below and the examples, macromers are often
designated by a code of the form xxKZn. xxK represents the molecular
weight of the backbone polymer, which is polyethylene glycol ("PEG")
unless otherwise stated, in thousands of Daltons. Z designates the
15 biodegradable linkage, using a code wherein where L is for lactic acid, G
is for glycolic acid, D is for dioxanone, C is for caprolactone, T is for
trimethylene carbonate, and n is the average number of degradable groups
in the block. The molecules are terminated with acrylic ester groups,
unless otherwise stated. This is sometimes also indicated by the suffix A2.
20 While the preferred biodegradable groups (in addition to carbonate
or dioxanone) are hydroxy acids, orthoesters, anhydrides, or other synthetic
or semisynthetic degradable linkages, natural materials may be used in the
biodegradable sections when their degree of degradability is su~cient for
the intended use of the macromer. Such biodegradable groups may
25 comprise natural or unnatural amino acids, carbohydrate residues, and
other natural linkages. Biodegradation time will be controlled by the local
availability of enzymes hydrolyzing such linkages. The availability of
such enzymes may be ascertained from the art or by routine
experimentation.


CA 02396229 2002-08-22
14
Water soluble regions.
Suitable water-soluble polymeric blocks include those prepared
from polyethylene glycol), polyethylene oxide), partially or fully
hydrolyzed polyvinyl alcohol), poly(vinylpyrrolidone),
5 p4ly(ethyloxazoline), polyethylene oxide)-co-poly(propylene oxide) block
copolymers (poloxamers and meroxapols), poloxamines, carboxymethyl
cellulose, hydroxyalkylated celluloses such as hydroxyethyl cellulose and
metthylhydroxypropyl cellulose, polypeptides, polynucleotides,
polysaccharides or carbohydrates such as Ficoll~ polysucrose, hyaluronic
10 add, dextran, heparan sulfate, chondroitin sulfate, heparin, or alginate,
and
proteins such as gelatin, collagen, albumin, or ovalbumin. Preferably, the
water-soluble polymeric blocks are made from polyethylene glycol) or
polyethylene oxide).
The soluble polymer blocks may be intrinsically biodegiadable or
15 may be poorly biodegradable or effectively non-biodegradable in the body.
In the latter two cases, the soluble blocks should be of sufficiently low
molecular weight to allow excretion. The maximum molecular weight to
allow excretion in human beings (or other species in which use is
intended) will vary with polymer type, but will often be about 40,000
20 daltons or below. Water-soluble natural polymers and synthetic
equivalents or derivatives, including polypeptides, polynucleotides, and
degradable polysaccharides, can be used.
The water-soluble blocks can be a single block with a molecular
weight of at least 600, preferably 2000 or more, and more preferably at
25 least 3000 Daltons. Alternatively, the water-soluble blocks can be two or
more water-soluble blocks which are joined by other groups. Such joining
groups can include biodegradable linkages, polymerizable linkages, or
both. For example, an unsaturated dicarboxylic acid, such as malefic,
fumaric, or aconitic acid, can be esteri$ed with degradable groups as
30 described below, and such linking groups can be conjugated at one or both
ends with hydrophilic groups such as polyethylene glycols. In another
embodiment, two or more PEG molecules can be joined by biodegradable


CA 02396229 2002-08-22
15
linkages including carbonate linkages, and subsequently be end-capped
with polymerizable groups.
Biodegradable Blocks.
The biodegradable blocks are preferably hydrolyzable under in vivo
5 conditions. At least one biodegradable region is a carbonate or dioxanone
linkage. Additional biodegradable polymeric blocks can include polymers
and oligomers of hydroxy acids or other biologically degradable polymers
that yield materials that are non-toxic or present as normal metabolites in
the body. Preferred poly(hydroxy acids are poly(glycolic acid),
10 poly(DL-lactic acid) and poly(L-lactic acid). Other useful materials
include poly(amino acids), poly(anhydrides), poly(orthoesters), and
poly(phosphoesters). Polylactones such as poly(epsilon-caprolactone),
poly(delta-valerolactone), poly(gamma-butyrotaetone)and poly
(beta-hydroxybutyrate), for example, are also useful.
15 Biodegradable regions can be constructed from monomers,
oligomers or polymers using linkages susceptible to biodegradation, such
as ester, peptide, anhydride, orthoester, and phosphoester bonds.
By varying the total amount of biodegradable groups, and selecting
the ratio between the number of carbonate or dioxanone linkages (which
20 are relatively slow to hydrolyze) and of lower hydroxy acid linkages
(especially glycolide or lactide, which hydrolyze relatively rapidly), the
degradation time of hydmgels formod from the macromers can be
controlled.
Carbonate and Dioianones
25 Any carbonate can be used to make the macromers. Preferred
carbonates are aliphatic carbonates, for maacimum biocompatibility. For
example, trimethylene carbonate and dimethyI carbonate are examples of
aliphatic carbonates. Lower dialkyl carbonates are joined to backbone
polymers by removal by distillation of alcohols formed by equilibration of
30 dialkyl carbonates with hydroxyl groups of the polymer.
More preferred carbonates are the cyclic carbonates, which can
react with hydroxy-terminated polymers without release of water. Suitable


CA 02396229 2002-08-22
16
cyclic carbonates include ethylene carbonate ( 1,3-dioxolan-2-one),
propylene carbonate (4-methyl -1,3-dioxolan-2-one), trimethylene
carbonate (1,3-dioxan-2-one) aad tetramethylene carbonate
(1,3-dioxepan-2-one). Under some reaction conditions, it is possible that
5 orthocarbonates may react to give carbonates, or that carbonates may react
with polyols via orthocarbonate intermediates, as described in Timberlake
et al, U. S.4,330,481. Thus, certain orthocarbonates, particularly dicyclic
orthocarbonates, can be suitable starting materials for forming the
carbonate-linked macromers.
10 Alternatively, suitable diols or polyols, including backbone
polymers, can be activated with phosgene to form chloroformates, as is
described in the art, and these active compounds can be mixed with
backbone polymers containing suitable groups, such as hydroxyl groups, to
form macromers containing carbonate linkages.
15 All of these materials are "carbonates" as used herein.
Suitable dioxsnones include dioxanone (p-dioxanone;
1,4-dioxan-2-one; 2-keto-l,4-dioxane), and the closely related materials
1,4-dioxolan-2-one, 1,4-dioxepan-2-one and 1,5-dioxepan-2-one. Lower
alkyl, for example C 1-C4 alkyl, derivatives of these compounds are also
20 contemplated, such as 2-methyl p-dioxanone (cyclic O-hydroxyethyl ether
of lactic acid).
Polymerizable Groups.
The term "polymerizable group" is defined as a reactive functional
group that has the capacity to form additional covalent bonds resulting in
25 macromer interlinking. Polymerizable groups specifically include groups
capable of polymerizing via free radical polymerization and groups capable
of polymerizing via cationic or heterolytic polymerization. Suitable
groups include, but are not limited to, ethylenically or acetylenically
unsaturated groups, isocyanates, epoxides (oxiranes), sulfhydryls,
30 succinimides, maleimides, amines, imines, amides, carboxylic acids,
sulfonic acids and phosphate groups. (Aliphatic hydroxy groups are not
consider~i to be reactive groups for the chemistry disclosed herein, except


CA 02396229 2002-08-22
17
in formulations which also contain groups capable of covalent crosslinking
with such hydroxyls.) Ethylenieally unsaturated groups include vinyl
groups such as vinyl ethers, N-vinyl amides, allyl groups, unsaturated
monocarboxylic acids, unsaturated dicarboxylic acids, and unsaturated
5 tricarboxylic acids. Unsaturated monocarboxylic acids include acrylic
acid, methacrylic acid and crotonic acid. Unsaturated diearboxylic acids
include malefic, fumaric, itaconic, mesaconic or citraconic acid.
Unsaturated tricarboxylic acids include aconitic acid. Polymerizable
groups may also be derivatives of such materials, such as acrylamide,
10 N-isopropylacrylamide, hydmxyethylacrylate, hydroxyethylmethacrylate,
and analogous vinyl and allyl compounds. Reactive group forming
compounds will preferably be available in a stable activated form, to allow
simple incorporation into the macromer. Examples of such materials are
(meth)acrylyl chloride, acrylic anhydride, and allyl glycidyl ether. The
15 polymerizable groups are preferably located at one or more ends of the
macromer. In a less preferred embodiment, the polymerizable groups can
be located within the macromer.
Polymerization is initiated by any convenient reaction, including
photopolymcrization, chemical or thermal free-radical polymerization,
20 redox reactions, cationic polymerization, and chemical reaction of active
groups (such as isocyanates, for example.) Polymerization is preferably
initiated using photoinitiators. Photoinitiators that generate a free radical
or a canon on exposure to UV light are well known to those of skill in the
. art. Free-radicals can also be formed in a relatively mild manner from
25 photon absorption of certain dyes and chemical compounds. The
polymeri~able groups are preferably polymerizable by free radical
polymerization. The preferred polymerizable groups are acrylates,
diacrylates, oligoacrylates, methacrylates, dimethacrylates,
oligomethacrylates, cinnamates, dicinnamates, oligocinnamates, and other
30 biologically acceptable photopolymerizable groups.
These groups can be polymerized using photoinitiators that generate
free radicals upon exposure to light, including W (ultraviolet) and IR


CA 02396229 2002-08-22
I8
(infrared) light, preferably long-wavelength ultraviolet light (LW(JV) or
visible light. LWL7V and visible light are preferred because they cause
less damage to tissue and other biological materials than short-wave UV
light. Useful photoinitiators are those which can be used to initiate
5 polymerization of the macromers without cytotoxicity aad within a short
time frame, minutes at most and most preferably seconds.
Exposure of dyes, preferably in combination with co-catalysts such
as amine, to light, preferably ;risible or LWtJV light, can generate free
radicals. Light absorption by the dye causes the dye to assume a triplet
10 state, and the triplet state subsequently reacts with the amine to form a
free radical which initiates polymerization, either directly or via a suitable
electron transfer reagent or co-catalyst, such as an amine. Polymerization
can be initiated by iwadiation with light at a wavelength of between about
200-1200 nm, most preferably in the long wavelength ultraviolet range or
15 visible range, 320 nm or higher, and most preferably between about 365
and 550 nm.
Numerous dyes can be used for photopolymerization. Suitable
dyes are well known to those of skill in the art. Preferred dyes include
erythrosin, phloxime, rose Bengal, thionine, camphorquinone, ethyl eosin,
20 eosin, methylene blue, riboflavin, 2,2-dimethyl-2-phenylacetophenone,
2-methoxy-2-phenylacetophenone, 2,2-dimethoxy-2-phenyl acetophenone,
other acetophenone derivatives, and camphorquinone. Suitable cocatalysts
include amines such as N-methyl diethanohmiine, N,N-dimethyl
benzylamine, triethanol amine, triethylarnine, dibenzyl amine,
25 N-benzylethanolamine, N-isopropyl benzylamine. Triethanolamine is a
preferred cocatalyst.
Suitable chemical, thermal and redox systems may initiate the
polymerization of unsaturated groups by generation of free radicals in the
initiator molecules, followed by transfer of these free radicals to the
30 unsaturated groups to initiate a chain reaction. Peroxides and other
pcroxygen compounds are well-known in this regard, and may be
considered as chemical or thermal initiators. Azobisbutyronitrile is a


CA 02396229 2002-08-22
19
chemical initiator. A combination of a transition metal, especially imn,
with a peroxygen and preferably a stabilizing agent such as glucuronic
acid allows generation of free radicals to initiate polymerization by a
cycling redox reaction.
5 Combinations of chemical or redax systems with photoinitiated
systems have been demonstrated to be egective in WO 96/29370, and are
a preferred initiation system for many applications of the macromers of the
present invention.
It is also possible to use the macromers with other types of linking
10 reactions. For example, a macromer could be constructed with amine
termination, with the amine considered as an active group; and another
macromer could be constructed with isocyanate terrmination, with the
isocyanate as the active group. On mixing, the materials will
spontaneously react to form a gel. Alternatively, an isocyanate-terminated
15 macromer could be polymerized and crosslinked with a mixtiwe of
diamines and triamines. Such a reaction is more diffcult to control than a
photoinitiated reac'on, but could be preferred for high volume
extracorporeal production of gels for implantation, perhaps as drug
delivery systems. Other pairs of reactants include maleimides with amines
20 or ~ sulfhydryls, or oxiranes with amines, sulfhydryls or hydroxyls.
Preferred Macromera
Preferably, the macromers contain between about 0.3% and 20% by
weight of carbonate residues or dioxanone residues, more preferably,
between about 0.5% and 15% carbonate or dioxanone residues, aad most
25 preferably, about 1 % to 5% carbonate or dioxanone residues. In those
embodiments where hydroxy acid residues are desired, the a~acromer
contains between about 0.1 and 10 residues per residue of carbonate or
dioxanone, more preferably betvvxn about 0.2 and 5, and most preferably
one or more such residue per macromer.
30 In a preferred embodiment, the macromer includes a core, an
extension on each end of the core, and an end cap on each extension. The
core is a hydrophilic polymer or oligomer; each extension is a


CA 02396229 2002-08-22
20
biodegradable oligomer comprising one or more carbonate or dioxanone
linkage; and each end cap comprises one or more functional groups
capable of cross-linking the macromers. In a particularly preferred
embodiment, the core includes hydrophilic polyethylene glycol) oligomers
5 with a molecular weight between about 400 and 40,000 Da; each extension
includes 1 to 10 residues selected from carbonate and dioxanone, and
optionally further included between one and five hydmxyacid residues,
preferably alpha hydroxy acid residues; wherein the total of all residues in
the extensions is sufficiently small to preserve water-solubility of the
10 macromer, being typically less than about 20% of the weight of the
macromer, more preferably 10% or less.
Preferably, each end cap includes a polymerizable group. The
preferred groups are free-radical (homolytically) polymerizable. More
preferably, they are ethylenically-unsahnat~ (i.e., containing
15 carbon-carbon double bonds), with a preferred molecular weight between
about 50 and 300 Da, which are capable of cross-linking and/or
polymerizing the macromers. A preferred embodiment incorporates a core
consisting of polyethylene glycol) oligomers of molecular weight about
25,000 Da; extensions including polycarbonate or poly(dioxanone)
20 oligomers with a molecular weight of about 200 to 1000 D, alone or in
combination with extensions formed of hydroxy acid oligomers; and end
caps consisting of acrylate moieties (which are about 55 Da molecular
weight).
Macromer Synthesis
25 The macromers can be synthesized using means well known to
those of skill in the art. General synthetic methods are found in the
literature, for example in U.S. Patent No. 5,410,016 to Hubbell et al., U.S.
Patent No. 4,243,775 to Rosensaft et al., and U.S. Patent No. 4,526,938 to
Churchill et al.
30 For example, a polyethylene glycol backbone can be reacted with
trimethylene carbonate (TMC) or a similar carbonate in the presence of a
Lewis acid catalyst, such as stannous octoate, to form a TMC-polyethylene


CA 02396229 2002-08-22
21
glycol terpolymer. The TMC-PEG polymer may optionally -be further
derivatized with additional degradable groups, such as lactate groups. The
terminal hydroxyl groups can then be reacted with acryloyl chloride in the
presence of a tertiary amine to end-cap the polymer with acrylate
S end-groups. Similar coupling chemistry can be employed for macromers
containing other water-soluble blocks, biodegradable blocks, and
polymerizable groups, particularly those containing hydroxyl groups.
When polyethylene glycol is reacted with TMC and a hydroxy acid
in the presence of an acidic catalyst, the reaction can be either
10 simultaneous or sequential. As shown in the examples below, the
simultaneous reaction will produce an at least partially random copolymer
of the three components. Sequential addition of a hydroxy acid after
reaction of the PEG with the TMC will tend to produce an inner
copolymer of TMC and one or more PEGs, which will statistically contain
15 more than one PEG residue linked by linkages derived from TMC, with
hydroxy acid largely at the ends of the (TMC, PEG) region. There is a
tendency for TM and other carbonate groups to rc-arrange by "back-biting"
during synthesis, which is why multiple PEG molecules can become
incorporated in the same maeromer. When the hydroxy acid contains a
20 secondary hydroxyl, as in lactic acid, then the tendency towards
rearrangement is reduced.
In principle, the degradable blocks or regions could be separately
synthesized and then coupled to the backbone regions. In practice, this
more complex reaction does not appear to be required to obtain useful
25 materials.
Sequentisl Addition
In a preferred embodime~, sequential addition of biodegradable
groups to a carbonate-containing macromer can be used to enhance
biodegradability of the macromer after capping with reactive end groups.
30 Upon reaction of, for example, trimethylene carbonate (TMC) with
polyethylene glycol (PEG), the TMC linkages in the resulting copolymers
have been shown to form end linked species of PEG, resulting in


CA 02396229 2002-08-22
22
segmented copolymers, i.e. PEG units coupled by one or more adjacent
TMC linkages. The length of the 'TMC segments can vary, and is believed
to exhibit a statistical distribution. Coupling may also be accomplished via
the carbonate subunit of TMC. These segmented PEGlTMC copolymers
5 form as a result of transesterif cation reactions involving the carbonate
linkages of the TMC segments during the TMC polymerization procass
when a PEG diol is used as an initiator. Similar behavior is expected if
other polyalkylene glycol initiators were used. The end-linking may begin
during the reaction of the TMC with the PEG, and completion of the end
10 linking and attainment of equilibrium is observable by a cessation of
increase of the viscosity of the solution.
If the product of this first reaction step is then reacted with a
reactive end-capping material, such as acryloyl chloride, a significant
percentage of the macromer end groups can be PEG hydroxyls, resulting
15 in the attachment of the reactive groups directly to one end of a
non-biodegradable PEG molecule. Such a reaction of the PEG/TMC
segmented copolymers can be prevental by adding additional segments of
other hydrolyzable co-monomers (e.g. lactate, glycolate, 1,4-dioxanone,
dioxepanone, caprolactone) on either end of the PEG/TMC segmented
20 copolymer. Some scrambling of the comonomer segments with the
PEG/TMC prepolymer is expected, but this can be minimized by using
proper reaction conditions. The basic PEGlTMC segments copolymer or
the further reacted PEGITMC/comonomer segmented terpolymer is then
further reacted to form crosslinksble macmmers by affixing tcactzve end
25 groups (such as acrylates) to provide a macromer with reactive
functionality. Subsequent reaction of the end groups in an aqueous
environment results in a biosbsorbable hydrogel. Similar segmented
structiu~es would be expected if another polyalkylene glycol (PAG) were
used, for example a poloxamer.
30 The copolymers and macxomers can have tailorable solubility and
solution viscosity properties. The hydrogels can have tailorable modulus
and degradation rate. For a given solution concentration in water, the


CA 02396229 2002-08-22
23
viscosity is affected by the degree of end linking, the length of the TMC
(and other hydrophobic species) segments, and the molecular weight of the
starting PAG. The modulus of the hydmgel is affected by the molecular
weight between crosslinks. The hydrogel degradation rate can be modified
5 by adding a second, more easily hydrolyzed comonomer (e.g, lactate,
glycolate, 1,4-dioxanone} as a segment on the ends of the basic PAGlTMC
copolymer prior to adding the crosslinkable end group to form the
macromer.
Some of these struct<u~es described herein are depicted below.
10 PEG, lactate and acrylate units arc used solely for purposes of
illustration.
SOME BASIC STRUCTURES:
(CHI CH~-O)x = PEG repeat unit~(PEG)x
(CO-(CH,); O)y = TMC repeat unit=(TMC)r
15 (CO-CH(CH,)~O)Z = Lactate repeat unit=(LA)Z
-CO-CH~H, . Acrylate end group=AA
SEGMENTED PEGrfMC COPOLYMER:
HO-(CO-(CH,),-O),.-[(CHI-CH~-O}~ (CO-(CH=); O)Y]~ H
20 or HO-(TMC)y-[(PEG)x-(TMC)y]n-H
HO-(CH(CH3)-CO); O-(CO-(CH,),-O}; [(CH; CHI O)x (CO-(CH=),-O),],-(C
O-CH(CH,)-O)= H
25 or HO-(LA)Z-(TMC)Y [(PEG)X (TMC)Y],; (LA)Z H
SEGMENTED PEGITIVIC MACROMER lacrvlated):
CHI CH-CO-O-(CO-(CH,); O),-[(CH=-CHI O); (CO-(CH,),-O),]; CO-CHI
30 H=
or AA-(TMC)y [(PEG)X-(TMC)yl"AA


CA 02396229 2002-08-22
24
SEGMENTED PEGffMC/Lactate TERPOL~~,V,~R MAf;~tOMER
lacrvlated):
~-(LA)= (TMC)y I(PEG)X C~~)Yl~ t~A)=-AA
5 ARplications for the Macrom~~~
Methods of Treatment
Generally, any medical condition which requires a coating or
sealing layer may be treated by the methods described herein to produce a
coating with better adherence. For example, lung tissue may be sealed
10 against air leakage after surgery using the priming technique. Likewise,
wounds may be closed; leakage of blood, serum, urine, cerebrospinal fluid,
air, mucus, tears, bowel contents or other bodily fluids may be stopped or
minimized; barriers may be applied to prevent post=surgical adhesions,
including those of the pelvis and abdomen, pericardium, spinal cord and
15 data, tendon and tendon sheath. The technique may also be useful for
treating exposed skin, in the repair or healing of incisions, abrasions,
burns, inflammation, and other conditions requiring application of a
coating to the outer surfaces of the body. The technique is also useful for
applying coatings to other body surfaces, such as the interior or exterior of
20 hollow organs, including blood vessels. In particlular, resrenosis of blood
vessels or other passages can be treated. The techniques can also be used
for attaching cell-containing matrices, or cells, to tissues, such as meniscus
or cartilage.
Sealing Leaks in Tissue
25 A prefewed application of the polymers is in a method of sealing
leaks, for example, leaks of gases and/or bodily fluids (such as blood,
cerebrospinal fluid, urine and bile), in tissue such as lung , wethra, ureter,
gastrointestinal tract, reproductive tract, liver, spleen, dare, and the
spinal
cord.
30 In thoracic surgery, uses include sealing of bronchopleural fistulas,
reduction of mediastinal bleeding, sealing of esophageal anastomoses, and
sealing of pulmonary staple or suture lines. In neurosurgery, uses include


CA 02396229 2002-08-22
25
ducal repairs, microvascular surgery, and peripheral nerve repair. In .
general surgery, uses include bowel anastomoses, liver resection, biiiary
duct repair, pancreatic surgery, lymph node resection, reduction of seroma
and hematoma formation, endoscopy-induced bleeding, plugging or sealing
5 of trocar incisions, and repair in general trauma, especially in emergency
procedures.
In plastic surgery, uses include shin grafts, burns, debridement of
eschars, and blepharoplasties (eyelid repair). In otorhinolaryngology
(ENT), uses include nasal packing, ossicular chain reconstruction, vocal
10 cord reconstruction and nasal repair. In opthalmology, uses include
corneal laceration or ulceration, and retinal detachment. In orthopedic
surgery, uses include tendon repair, bone repair, including filling of
defects, and meniscus repairs. In gynecology/obstetrics, uses include
treatment of myotomies, repair following adhesiolysis, and prevention of
15 adhesions. In umlogy, sealing and repair of damaged ducts, and treatment
after partial nephrectomy are potential uses. Sealing can also be of use in
stopping diffuse bleeding in any of a variety of situations, including
especially treatment of hemophiliacs. In dental surgery, uses include
treatment of periodontal disease and repair after tooth extraction. Repair
20 of incisions made for laparoscopy or other endoscopic procedures, and of
other openings made for surgical purposes, are other uses. Additional uses
include separation of tissues to prevent damage ~by Tugging during healing.
Similar uses can be made in veterinary procedures. In each case,
appropriate biologically active components may be included in the sealing
25 or bonding materials.
The method involves pruning the surface of the tissue with a
polymerization initiator, applying a macromer solution that also contains
one or more polymerization initiators to the surface of the tissue to be
coated, and then polymerizing the macromer. Preferably, the
30 polymerization initiator comprises a photoinitiator.
Applying the initiator to surface of the tissue before adding the
macmmer solution polymerizes the macromer at the interface between the


CA 02396229 2002-08-22
26
solution and the tissue surface. This "interfacial polymerization" provides
excellent adherence of the resulting polymer to the tissue surface.
Providing an initiator in the macromer solution allows a relatively thick,
for example 1 mm to 10 mm, layer of polymer to be formed on the tissue
5 surface., Relatively .thick polymer layers may be required to effectively
seal some types of tissue, for example, lung tissue or darn, depending on
the size of the leak.
An advantage of the macromers when prepa~~ed with at least one
carbonate group is that during the synthesis of the macromer, short blocks
10 of non-biodegradable but excretable polymer, such as polyethylene oxide
chains of up to about 40,000 D, can become linked by carbonate groups so
give higher molecular weights to the macmmers while preserving the
biodegradability to secretable products of the macmmer. It is believed that
the higher molecular weights increase the elasticity of the final hydrogel.
1 S This is an important and useful property when the polymer must be readily
and repeatedly stretched, as in a sealant layer applied to lung tissue. High
elasticity can also be provided by linking nondegradable blocks with other
polyfunctional linkers, such as dicarboxylic acids. However, since the
synthetic chemistry required to make such macromers can be more
20 complex than the simple reactions required for carbonate-based linking,
this method is less preferred.
Prevention of Surgical Adhesions.
Another preferred application is a method of reducing formation of
adhesions after a surgical procedure in a patient. The method involves
25 coating damaged tissue surfaces in a patient with an aqueous solution of a
light sensitive free-radical polymerization initiator and a macromer
solution as described above. The coated tissue surfaces are exposed to
light sufficient to polymerize the macromer. The light-sensitive
free-radical polymerization initiator may be a single compound (e.g.,
30 2,2-dimethoxy-2-phenyl acetophenone) or a combination of a dye and a
cocatalyst (e.g., ethyl eosin or eosin Y, and triethanolamine).


CA 02396229 2002-08-22
27
Controlled delivery of -incorporated agents.
Another preferred application involves locally applying an
incorporated agent, such as a prophylactic, therapeutic or diagnostic agent,
to tissue surfaces of a patient. The method includes the steps of mixing an
5 agent to be incorporated with an aqueous solution including a suitable
polymerization initiator, such as a light-sensitive free-radical
polymerization initiator, and a macromer, to form a coating mixture.
Tissue surfaces are coated with the coating mixture and the macromer is
polymerized, for example, by exposure of the coating mixture to an
10 effective amount of Iight of an appropriate wavelength.
Any of a variety of therapeutic, prophylactic or diagnostic agents
can be delivered using these methods. Examples include synthetic and
natural inorganic and organic compounds such as proteins ( 100 amino acid
residues or more), peptides (less than 100 amino acid residues),
15 carbohydrates, lipids, nucleic acid molecules, and small synthetic
materials
such as ethical drugs, having therapeutic, prophylactic or diagnostic
activities. Nucleic acid molecules include genes, antisense molecules
which bind to complementary DNA to inhibit transcription, aptamers,
triple helix forming oligomers and ribozymes. The agents to be delivered
20 can have a variety of biological activities. Diagnostic agents such as
radiolabelled compounds, enzymatically labeled compounds, fluorescently
labeled compounds, and other detectable agents can also be incorporated.
Compounds with a wide range of molecular weights can be incorporated,
for example, between 100 and 500,000 grams or more per mole.
25 Therapeutic or prophylactic compounds ("drugs") of particular
interest are those whose efficacy in treatment of a localized medical
condition is increase by local delivery of the compound at or near the site
of the localized medical condition. Examples of classes of such drugs are
those which inhibit the formation or re-formation of scars or adhesions;
30 those which prevent unwanted proliferation of vascular tissue or other
luminal tissue; and growth factors, cytolanes, etc. which only needs to be
effective locally.


CA 02396229 2002-08-22
28
Imaging agents which may be utilized include commercially
available agents used in positron emission tomography (PET), computer
assisted tomography (CAT), single photon emission computerized
tomography, x-ray, fluoroscopy, and magnetic resonance imaging (NiRI}.
5 Examples of suitable materials for use as contrast agents in MRI
include the gadolinium chelates currently available, such as diethylene
triamine pentacetic acid (DTPA} and gadopentotate dimeglumine, as well
as iron, magnesium, manganese, copper and chromium.
Examples of materials useful for CAT and x-rays include iodine
10 based materials for intravenous administration, such as ionic monomers
typified by diatrizoate and iothalamate, non-ionic monomers such as
iopamidol, isohexol, and ioversol, non-ionic dimers, such as iotrol and
iodixanol, and ionic dimers, for example, ioxagalte.
Hydrogels incorporating these agents can be detected using standard
15 techniques available in the art and commercially available equipment.
The macmmers are particularly useful for delivering hydrophilic
and/or labile materials. Because the macmmer is water-soluble, water can
penetrate the polymer and dissolve or extract incorporated hydrophilic
materials. Labile materials can be incorporated without exposure of the
20 material to organic solvents which would destroy biological activity.
Hydrophobic materials may also be incorporated, if the rate of dissolution
of the hydrophobic material andlor the gel matrix is su~ciently rapid to
release the material at a therapeutically-effective rate. In all cases, the
polymerized hydrogel will tend to protect the therapeutic material from
25 attack by biological activities of the subject, such as enzyme activity.
In a variation of the method for controlled drug delivery, the
macromers are polymerized with incorporated
Preferred Macromers
Preferably, the macromers contain between about 0.3% and 20% by
30 weight of carbonate residues or dioxanone residues, more preferably,
between about 0.5% and 15% carbonate or dioxanone residues, and most
preferably, about 1% to 5% carbonate or dioxanone residues. In those


CA 02396229 2002-08-22
29
embodiments where hydroxy acid residues are desired, the macromer
contains between about 0.1 and 10 residues per residue of carbonate or
dioxanone, more preferably between about 0.2 and 5, and most preferably
one or more such residue per macromer.
5 In a preferred embodiment, the macromer includes a core, an
extension on each end of the core, and an end cap on each extension. The
core is a hydrophilic polymer or oligomer; each extension is a
biodegradable oligomer comprising one or more carbonate or dioxanone
linkage; and each end cap comprises one or more functional groups
10 capable of cross-linking the macromers. In a particularly preferred
embodiment, the core includes hydrophilic polyethylene glycol) oligomers
with a molecular weight between about 400 and 40,000 Da; each extension
includes 1 to 10 residues selected from carbonate and dioxanone, and
optionally further includeds between one and five hydroxyacid residues,
15 preferably alpha-hydroxy acid residues; wherein the total of all residues
in
the extensions is sufficiently small to preserve water-solubility of the
macromer, being typically less than about 20% of the weight of the
macromer, more preferably 10% or less.
Preferably, each end cap includes a polymerizable group. The
20 preferred groups are free-radical (homolyticaily) polymerizable. More
preferably, they are ethylenically-unsatiuated (i.e., containing
carbon-carbon double bonds), with a preferred molecular weight between
about 50 and 300 Da, which are capable of cross-linking and/or
polymerizing the macromers. A preferred embodiment incorporates a core
25 consisting of polyethylene glycol) oligomers of molecular weight about
25,000 Da; extensions including polycarbonate or poly(dioxanone)
oligomers with a molecular weight of about 200 to 1000 D, alone or in
combination with extensions formed of hydroxy acid oligomers; and end
caps consisting of acrylate moieties (which are about 55 Da molecular
30 weight).


CA 02396229 2002-08-22
30
Tissue Adhesives.
The macromers, and hydrogels formed therefrom, can also be used
to adhere tissue surfaces in a patient. The macromer is mixed with a
suitable polymerization initiator system, such as a photoinitiator or
5 photoinitiator/amine mixture, to form an aqueous mixture. The mixture is
applied to a tissue surface to which tissue adhesion is desired. The tissue
surface is contacted with the tissue with which adhesion is desired,
forming a tissue junction. The macromers are then polymerized at the
tissue junction.
10 Such a technique can be used to hold surgically severed tissue in
apposition during the healing prods, thereby replacing or supplementing
the use of sutures, staples, etc. In addition, such a gel may also be used to
form a protective barrier.
Coating of Surfaces
15 Surfaces to be coated include biologically-related surfaces of all
kinds, and include the surface of drug delivery devices such as catheters or
prosthetic implants. Any tissue or cell surface is contemplated, as well as
the surface of a device to be used in the body or in contact with bodily
fluids. A coating may be applied to the surface of any of these, in an
20 amount effective to improve tenacity of adherence. Moreover, the
technique may be used to adhere surfaces to each other. For example,
wounds in living tissue may be bonded or sealed using this technique or
preformed medical appliances may be bonded to tissue. Examples of such
applications are grafts, such as vascular grafts; implants, such as heart
25 valves, pacemakers, artificial corneas, and bone reinforcements; supporting
materials, such as meshes used to seal or reconstruct openings; and other
tissue-non-tissue interfaces. A particularly important class of tissue
surfaces is those which are friable, and therefore will not support sutures
well. Adherent coatings can seal the suture lines, support sutured areas
30 against mechanical stress, or substitute entirely for sutures when
mechanical stress is low. Examples of such situations include vascular


CA 02396229 2002-08-22
31
anastomosis, nerve repair, repair of the cornea or the cochlea, and repair of
the lung, liver, kidney and spleen.
The priming technique can also be used on non-tissue surfaces in
general, where useful bonds may be formed bin similar or dissimilar
5 substances, and solid or gel coatings are tightly adhered to surfaces. In
particular, a pre-formed gel, or other fragile material, may be tightly
adhered to a supporting material by this method.
The priming method is advantageous because it can be used to coat
and or to bond together any of a wide variety of surfaces. These include
10 all surfaces of the living body, and surfaces of medical devices, implants,
wound dressings and other body-contacting atrificial or nahwal surfaces.
These include, but are not limited to, at least one surface selected from the
following: a surface of the respiratory tract, the meninges, the synovial
spaces of the body, the peritoneum, the pericardium, the synovia of the
15 tendons and joints, the renal capsule and other serosae, the dermis and
epidermis, the site of an anastomosis, a suture, a staple, a puncture, an
incision, a laceration, or an apposition of tissue, a ureter or urethra, a
bowel, the esophagus , the patella, a tendon or ligament, bone or cartilage,
the stomach, the bile duct, the bladder, arteries and veins; and devices such
20 as percutaneous catheters (e.g. central venous catheters), pereutaneous
cannulae (e.g. for ventricular assist devices), urinary catheters,
percutaneous electrical wires, ostomy appliances, electrodes (surface and
implanted), and implants including pacemakers, defibrillators. and tissue
augmentations.


CA 02396229 2002-08-22
32
In a particularly preferred application of these macromers, an ultra
thin coating is applied to the surface of a tissue, most preferably the inside
surface of a blood vessel. Such coatings can be used to treat or prevent
stenosis or restenosis of blood vessels. A polymerization initiator,
5 preferably a photoinitiator, is applied to the surface of the tissue,
allowed
to stain the tissue, and, optionally, the excess photoinitiator is removed by
dilution or rinsing. After the initiator has been applied to the tissue, the
macromer solution is applied and the macromer is polymerized. As
demonstrated below, this method is capable of creating a uniform
10 polymeric coating of between about one and 300 microns in thickness,
more preferably about ten to 200 microns, most preferably 20 to 80
microns, which does not evoke thrombosis during its residence at the site.
The surface of medical devices can be coated with the macromers
using interfacial polymerization, bulls polymerization, or both, as discussed
15 above. Coating layers applied using interfacial polymerization or a
combination of interfacial and bulk polymerization typically adhere more
strongly to the medical devices than those prepared using only bulk
polymerization.
APPLICATION TECI~NIOUE~AND DEVICES
20 Both priming and polymer addition may be accomplished by simple
dripping of material onto the surface to be coated. This sera be
accomplished using common devices such as a syringe, a pipet, or a hose,
depending on scale. More uniform applications may be obtained using an
. applicator, such as a brush, a pad, a sponge, a cloth, or a spreading device
25 such as a finger, a coating blade, a balloon, or a skimming device. These
may further be used to rub the surface to improve penetration of the
primer or the monomer, or to mix primer and monomer in situ on the
surface. In large-scale applications, fluid layers may be applied with
large-scale coating machinery, including roll coatcrs, curtain coaters,
30 gravure and reverse gravure devices, and any of the coating devices known
in the art. Sprayers may be used at any scale, especially for lower-
viscosity primers or polymerizable monomer layers.


CA 02396229 2002-08-22
33
Application techniques and devices may be combined, as in
applying fluid from a syringe, and then rubbing it into the surface with a
forger tip. Such operations may be repeated, as in applying drops of
priming initiator; rubbing these into the surface with a brush; repeating
5 this operation; adding monomer solution; rubbing it in; and finally
applying additional layers of monomer before or during the application of
curing means, such as light, heat, or slow release of peroxide radicals.
An additional application means which is required in many coating
techniques described herein, and in particular in the preferred coating
10 method which uses ghotoinitiation to cure the monomer, is a light source.
For large-scale application, flood lamps and similar devices are useful. In
small, localized applications, such as tissue sealing and coating, it may be
preferable to use a localized source such as a fiber optic or light guide,
which can project radiation of the appropriate wavelength onto the site to
15 be treated to cause polymerization of the monomer. Also, a light emitter
could be carried on a device, as a miniature bulb. A focused beam from a
remote source could be suitable if, for example, the surface was exposed.
In exposed surfaces, it is possible that ambient light could be sufficient to
polymerize the coating, especially at high initiator levels.
20 Each of the applications means can be separate, so that a kit of
application means could contain, for example, one or more containers or
reservoirs, one or more pads or brushes, and if required at least one light
guide. The application means could also be combined in whole or in part.
For example, a dripping device, such as a tube, could be combined with a
25 spreading device, such as a brush. These could further be combined with a
light guide. Such combination devices are especially desirable in treatment
of living organisms, and especially humans, to maximize the simplicity of
a procedure and the probability of correctly conducting it.
COMPLIANCE PROPERTIES
30 The compliance properties of the material herein described are
those of the material after it has polymerized to form a polymerized
material. As used herein, "polymerized material" includes material which


CA 02396229 2002-08-22
34
forms by the ionic or covalent reaction of monomer precurser molecules.
Preferably, the polymerized material is formed by covalent reactions of the
monomers. It can be very diff cult to measure the elastic properties of the
material when adhered to tissue. The mechanical properties are therefore
5 when appropriate measured on samples made in vitro, either in a mold, or,
as in the lap-shear test, in contact with standardized tissue. Such
measurements must be corrected to conditions applicable to tissue
treatment, including the diluting effects of polymerization reagents, or of
fluids on the tissue. Thus, a sealing solution may be applied to tissue at a
10 concentration of 30%, but in the coating process it may be diluted to 15%
effective concentration by dilution with blood or plasma. Similarly,
especially in the case of fibrin sealant, the polymer concentration may be
reduced by mixing with polymerizing reagents, either in bulk or by
spraying. Where appropriate, such con~ections have been taken into
15 account in the descriptions herein. Materials may be equilibrated with
water before testing either by absorption or syneresis.
In light of these observations, an effective material for forming a
compliant coating or sealant preferably has a strain or elongation before
fracture substantially similar to or at least as great as the expected strain
20 during normal use of the tissue to which it is applied, and the elongation
of the polymerized material is preferably reversible. This is to avoid
either detachment from the tissue or fracture, or limitation of the tissue's
natural expansion. Preferably, the effective compliant material will have a
reversible elongation at least about 150'/o as great, more preferably at least
25 about 200~/o as great, and still more preferably at least about 300% as
great as the expected strain of the tissue.
The polymerized material thus may be designed and selected for
application to different tissue, to have an elongation at rupture which is
similar to or greater than the elongation of the tissue in vivo during its
30 function. The elongation at n~tu~e of the polymerized material can be,
for example, greater than 100% or 200%, or optionally greater than 300%
or 400%. In some embodiments, the elongation at rupture of the


CA 02396229 2002-08-22
35
polymerized material may be between for example 100'/o and 700%,
depending on the tissue properties. In some applications, an elongation at
rupture greater than 700% is useful.
In addition, the compliant material, for example in sealant
5 applications, preferably should have a normalized compliance that is
comparable in magnitude to the normalized compliance of the tissue to
which it is applied. The material will be operative even when the
material's normalized compliance is much greater than the normalized
compliance of the tissue.
10 In cases where minimal modification of the natural expansion and
contraction of a tissue is desired, the preferred range of the normalized
compliance ratio extends from about 0.05 to about 3, preferably from
about 0.1 to about 2.0, and more preferably from about 0.1 to about 1Ø
In some cases, for example when the tissue is lung tissue, a value of the
I S elastic modules of less than about 150 kPa, preferably less than 100 kPa,
more preferably less than about 50 kPa, and most preferably less than
about 30 kPa is preferred.
To obtain the desired ratio of the normalized compliance of the
polymerized material to the normalized compliance of tissue, the overall
20 force required to stretch the sealant layer should be adjusted, since that
of
the tissue is fixed. The adjustment can be accomplished by any of several
known methods, including the alteration of the thickness of the layer of
the polymerized material, or the variation of the polymer concentration, or
of the polymer crosslink density, or of other properties of the material.
25 The properties of the precursor materials and the reaction conditions may
be adjusted to produce desired other properties of the polymerized
material, such as sealant or adhesive properties, or controlled degradation
and drug release properties.
Where prevention of tissue deformation is desired, for example
30 during a healing period, the parameters of the tissue coating can be
adjusted so that the normalized compliance ratio is significantly in excess
of 1.


CA 02396229 2002-08-22
r
36
The adherence of the polymerized material to the tissue is
important in order to obtain the benefits of proper compliance properties.
An adherence of at least about 20 gmlcm2 in a single or double lap shear
test is preferable for many applications. Use of priming technology,
described elsewhere in this application, is an effective method for
obtaining such values. In some applications, such as the use of the
polymerized material as a tissue sealant, adherence values of about 30
gmlcm2 arc preferred, and values at or above 40 gm/cmZ are more
preferred.
In many applications, such as tissue sealing, the viscosity of the
precursor materials can be tailored to obtain optimal coatings. Higher
viscosities can favor retention of the uncured or unpolymtrized sealant at
the site of application, and minimize displacement of the sealant by the
presence of bodily fluids at the surface. However, higher viseosities make
the material more diffcult to apply. A suitable range of viscosity; for
example, for the sealant portion of a sealing system is in the range of
about 200 cP (centipoise) to about 40,000, preferably about 500 to about
5000 cP, and more preferably about 700 to about 1200 cP. For lung, a
suitable range of viscosity is about 900 to 1000 cP. The optimal viscosity
will depend on the site of application and the nature of the condition
which is to be alleviated by the application of the material.
The present invention will be more fully understood by reference to
the following non-limiting examples.
Ezample 1: General Synthaia of Macromers: Melt Method.
Methods analogous to those described in U.S. Patent No. 4,526,938
to Churchill et al, were used to form derivatized PEG by the melt method.
Polyethylene glycol (PEG) was obtained commercially. The molecular
weight listed an the label was assumed to be the molecular weight of the
material. The PEG was optionally dissolved in methanol and purified by
passage over an ion exchange resin, and dried.
Purified or as-supplied PEG was charged to a reactor, optionally
with a small amount of xylene, and heated for five to six hours at about


CA 02396229 2002-08-22
" . 37
l I0°C (note: all temperatures herein are in degrees Celsius) under
vacuum
to complete removal of water. After cooling under vacuum, the flask was
placed in a glove bag, the materials for forming the biodegradable linkages
(including T (trimethylene carbonate) and L (iactide)) were added to the
PEG, and the temperature was raised to about 160-165°C under an
argon
blanket.
After dissolution of the reactants in the melted PEG, a catalyst,
typically stannous octoate, was added, the temperature was raised to
185°C, and ring-opening addition was allowed to proceed for about 3
hours, with stirring under argon. The PEG-(T,L) intermediate could be
further reacted at this stage, but typically was freed of unreacted
monomers by precipitation in hexane, recovery and drying.
The purified intermediate, for example, PEG-(TnLm), where "n" is
the number of T gmups and "m" is the number of L groups, or the
original reaction mixture without purification, was taken up in toluene, and
an agent capable of adding unsaturated linkages, such as acryloyl chloride,
was added, typically in excess, under mild heating (e.g., about 50°C)
and
in the presence of an acid-neutralizing agent such as triethylamine.
Suitable reactant ratios were found to be 1 ml acryloyl chloride and 1.8
ml~ triethylamine per 30 grams of PEG. The endcapped macromer,
PEG-(T,L~A2, was purified by precipitation in hexane, recovered and
dried. Stabilizer was optionally added at this stage. The extent of
incorporation of monomers was determined by NMR.
A sinular procedure was used to prepare other macromers.
PEG-(Tn)-A2, PEG-(Dn, Gm~A2, where D is dioxanone and G is
glycolide, and like materials were formed by similar procedures. Synthesis
of macromers based on other starting hydrophilic blocks follows similar
procedures, with adjustment in precipitation conditions as required. In a
synthesis with mufti-hydroxy compounds, such as polyvinyl alcohol, the
water would be removed azeotropically under mild reflex in, e.g., toluene;
and the degradable linkages are preferably synthesized by polymerization
onto the hydroxy compound as described above, although such blocks


CA 02396229 2002-08-22
. ~ 38
could be added as preformed activated acrylated blocks, for example, using
a carbodiimide derivative of ~e acylated poly(degradable linkage), if
greater contml were required.
Example 2: Synthesis of PEGTMC and PEG-TMC-Lactide
Macromera.
35K(T8)A2 ("35KT" in the examples below) was made from
purified PEG of nominal molecular weight 35,000 Daltons by the melt
procedure as described above. T was charged into the reactor at a nominal
molar ratio of 13:1 to the PEG to obtain this result. The final actual
acrylate incorporation averaged 1.6 per PEG molecule, or about 2 acrylates
per macromer.
35K(T7L2}A2 ("35KTL") contained about 7 T units (6.88
measured) and 2 lactate units ( 1.86 measured) as synthesized. (Note that
there are 2 lactate units per lactide molecule.) T and L were charged at
nominal molar ratios of 10:1 and 3:1 relative to PEG.
20K(T30L15)A2 contained about 30 T units and 15 lactide units
per 20,000 Daltons PEG molecule. The actual acrylate to PEG ratio was
1.42.
Ezample 3: Seal pressure test on latex to measure strength
and elasticity
Polyethylene glycol)-lactide-trimethylene carbonate terpolymers
endcapped with acrylate esters were evaluated using a seal pressure test
apparatus to determine the failure pressure for coatings prepared using the
macromers.
One of the materials tested had a polyethylene glycol) molecular
weight of 20,000 Daltons ("20 kiloDaltons"), a lactate incorporation of
13.8 and a trimethylene carbonate incorporation of 16.0, with nominal
acrylation of 2 per macromer ("20KTL"). Also tested were 35 kiloDalton
PEG esterified with about 8 TMC linkages and then endcapped with
acrylates ("35KT"), and 35 kiloDalton PEG esterified with about 8 TMC '
and about 8 lactate groups ("35 KTL"), both also acrylated. The reagents
applied were "primer" and "sealant". The complete system contained both


CA 02396229 2002-08-22
39
a photoinitiation system (Eosin Y/triethanolamine) and a redox initiation
system (ferrous gluconate/fructose, plus t-butylhydroperoxide after mixing)
which did not cause significant polymerization of the macromer until both
mixed (primer and sealant) and activated by light.
5 Primer solution contained Eosin Y (2000 ppm, w/w), 5004 ppm
ferrous gluconate, 10,000 ppm (1%) fructose, 30,000 ppm NaCI, and 30%
w/w of 3.SKL5 macromer (made according to US 5,410,016). Primer was
applied to a 2 cm x 2 cm piece of latex film (from a latex examination
glove; about 1 mm thick) with a 6 mm diameter hole created in the center.
10 A toroidal Teflon~ fluoropolymer template with a 1 cm. diameter central
hole was placed on the latex film to control the area of application of the
sealant, by limiting its spread.
Sealant solution contained macromer (in this example, 10% or 20%
w/w of one of the macromers described above) dissolved in an aqueous
15 solution containing isotonic saline, 90 mM triethanolamine as buffer and
electron transfer component, Eosin Y (20 ppm) as a photoinitiator, 4000
ppm vinylcaprolactam as comonomer, and 125 ppm t-butylhydmperoxide
as part of the light-sensitize redox initiation system. Two drops of
sealant were dispensed inside the template above the hole and then
20 carefully mixed in with the primer, using a brush. Three more drops of
sealant were dispensed; and then the acre was illuminated with visible light
from a xenon arc lamp (450-550 nm) at an intensity of 100 mW/emz for
40 seconds. Samples were placed in phosphate buffered saline (pH 7.4) at
37°C for different times (t~, 4 hours, 1 days, 3 days, 6 days and 10
25 days).
Samples were evaluated at each time point using a seal pressure
test apparatus to determine the failure pressure. The test apparatus was a
modified membrane holder, in which the latex sample was clamped at the
edges between gaskets. Pressure was then applied to the side of the latex
30 away from the polymer seal, and the press~nre required to rupture the seal
was measured.


CA 02396229 2002-08-22
Figure 1 shows the results obtained with five different sealant
materials. The seal pressure decreases over the course of time, presumably
due to a combination of swelling of the hydrogel due to hydration and
programmed degradation of the hydrogel.
5 Example 4: Bioabsorption in-vivo
Polyethylene glycol~trimethylene carbonate copolymers, optionally
containing lactate, and endcapped with acryiate esters, were evaluated.
Two of the materials described in Example 3 were used (20KTL and
35KT). The macromers were polymerized using visible light illumination
10 from a xenon arc lamp (450-550 nm) at an intensity of 100 mW/cmz in a
sealant solution containing macromer, eosin, triethanolamine,
vinylcaprolactam, t-butylhydroperoxide and saline as in Example 3.
Macromer concentration was 10% for 20KTL and 20% for 35KT.
The absorption of the sealant was determined by subcutaneous
15 implants in rats. Five female Sprague Dawley rats (250-300 g) were used
in this study. The animals were anesthetized by intramuscular ("IM")
injection of 3.2 mUkg mixture of Ketamine (52.4 mglkg), Xylazine (2.8
mglkg), Acepromazine (0.7 mg/kg). Four 1 cm longitudinal incisions
were made through the skin on the back. Two incisions were made on
20 each side of the spinal column, spaced 1 cm off the midline and 2 cm
apart. A 2 X 2 cm pocket was created at each incision site by blunt
dissection. Preformed hydrogel disks were prepared using sterile
technique. One hundred microliters of sealant solution was placed in the
bottom of one well of a standard 24-well tissue culture plate, and was
25 illuminated for 40 sec at 100 mW/cm2, producing a thin disc about 18
mm. in diameter. One disk was placed in each subcutaneous pocket.
Incisions were then closed with surgical staples. Animals were euthanized
at intervals by COZ inhalation. Incisions were opened and gross
observations were recorded. Each site was harvested and analyzed by gel
30 permeation chromatography for mass loss.
Figures 2A and 2B show that the 20KTL based hydrogels were
completely absorbed in 20 days in vivo (Figure 2A), whereas the 35KT


CA 02396229 2002-08-22
41
based hydmgels were partially absorbed (60% weight loss) in 154 days
(Figure 2B). This illustrates the significant effect of rapidly-degrading
linkages such as lactate groups.
Example 5: Sealing of Dural Leak in CaOine Craniotomy
5 A polyethylene glycol)-trimethylene carbonate-lactate copolymer
endcapped with acrylate ester (20KTL, from Example 2) was evaluat~i for
its ability to seal fluid leaks in membranes in vivo. The polyethylene
glycol) molecular weight used was 20,000 Da. The lactate incorporation
was 13.8 and the trimethylene carbonate incorporation was 16Ø The
10 macromer was fully acrylatod.
The performance of the sealant was evaluated in a ducal incision
injury model in three mongrel canines. The animals were pre-anesthetized,
intubated and maintained on isoflurane gas anesthesia. With the head
elevated, a bilateral craniotomy was created. Two ducal incisions, each 2
1 S cm. long, were made, one on the left side and one on the right side.
Incisions were closed using 3 simple interrupted 4-0 to 6-0 silk sutures
spaced approximately 5 mm apart. Cerebrospinal fluid (CSF) pressure was
raised by inflating the lungs to 20 cm H20, and the leak was assessed. All
incisions were found to leak, as expected from the closure.
20 The control side (left) received no additional closure of the
incision. For the treatment side (right), the primer (a low viscosity
solution; described in example 4) was applied aad mixed with the fluid on
the tissue interface. The sealant ( 10% w/w solution of 20KTL (described
above) with other materials as in Example 4) was layered over the primer,
25 and the primer and sealant were mixed with a brush. Illumination for 40
sec. with a visible xenon arc lamp (450-550 nm) at an intensity of 100
mW/cm2 was then performed to complete the polymerization.
The leaks were re-verified by raising the CSF pressure by inflating
the lungs to 20 cm HZO. Leakage was observed on the control side, but
30 not on the experimental side. The bone flaps were replaced and the
incision was repaired.


CA 02396229 2002-08-22
42
All animals were euthanized at 21 days and the craniotomy was
re-opened. Adhesions between the dare and the bone flap were recorded,
and the dare repair sites were ~ for evidence of CSF fluid leaks.
Dural repair sites were dissected free from underlying cortical tissue and
5 the presence of adhesions noted. The tissues were harvested, rinsed in
saline, and fixed in 10% neutral buffered formalin. Hematoxylin and
eosin stained histological sections were taken.
At the time of explant, the control sites showed a slight fibrosis
present between the data mater and calvarium. No inflammation was
10 detected. The sealant was not apparent in two out of three animals and
only small amounts were present in the third animal. The dural edges
were approximated. Defects in the bone (resulting from the surgery) were
filled with fibro-osseous tissue at 21 days, in both control and treated
sites.
Normal healing appeared to be taking place, both visually and
15 histologically.
EXAMPLE 6. Solution Synthesis
Macromers can also be made by synthesis in solution. While
requiring additional waste disposal, the solution synthesis is more easily
controlled (compared to the melt synthesis of Example 1 or 2), and is
20 preferred for most applications. This example also illustrates the practice
of sequential addition of monomers; the method is also useful for
simultaneous addition of monomers.
35KTLA was made by dissolving 75 g of 35 kiloDalton
' (nominal) PEG in toluene to 20% w/w concentration, and was dried by
25 nitrogen purge for 3 hours at 1 O8° C. 3.06 G TMC ( 14 mole
equivalents
per PEG) and 0.024 g stannous octoate catalyst were added, and the
solution was held at 108° for 4 hours with slitting. Then 0.46 g (1.5
equiv..) lactide was added, and stirring continued for 2 hrs. Then 300 ml
toluene was added to give about a 10% wt/vol solution of polymer. After
30 cooling the solution to about 50°, 4.6 g of triethylamine and 2.5 ml
of
acryloyl chloride wire added. The solution was stirred for 20 min. at
about 50. Acrylated macromer was recovered by precipitation and


CA 02396229 2002-08-22
43
optionally filtration as described in Ex. 1 and 2. The resulting polymer
contained 5 TMC residues and 1.2 lactate residues per PEG molecule, and
ratios of lactate :acrylate of 0.6.
EXAMPLE 7. In Vitro Degradation
35KTLA2 was synthesized as described in Example 6. The
completed macromer had a TMC:PEG molar ratio of 3.57; an acrylate:
PEG ratio of 1.52; a lactate: PEG ratio of 1.39; and contained 766 ppm
TMC. On gel permeation chromatography, the macromer was 48.1
"monomer" (one PEG unit per macromer molecule), 46.3 % "dimer" two
PEG units per macromer molecule), 5.4% "trimer" and 0.1 % higher
oligomer.
Discs of the macromer were made as described in example 4 and
were incubated in phosphate-buffered saline, pH 7.4, at 37° and
57°. At
57°, half of the mass was lost at about 140 hrs, while at 37°,
half the mass
was lost at about 42 days. Mass loss was determined by rinsing the
specimen, drying to constant weight, and correcting for the amount of
buffer and salt present.
EXAMPLE 8. Dioxaaone-containing Mscromers
Dioxanone (1,4-dioxan-2-one; p-dioxanone) was synthesized from
DEG (diethylene glycol) essentially according to US 2,807,629, Example
1. Two kilograms of DEG were mixed with 40 g. copper chmmite
(Aldrich) and heated at about 230° for 4 hours under nitrogen purge,
which displaced generated hydrogen. Dioxanone and DEG were distilled
from the mixture under vacuum at about 50° pot temperature. DEG was
partially removed by extraction in cold (4°) diethyl ether. . The
partially
purified material was dissolved in chloroform and applied to a silica
column equilibrated in chloroform. Dioxanone was recovered in the initial
fractions.
Macromcr 35KDA was made by drying overnight (vacuum, 110°)
15 g of 35 kiloDalton PEG, 1.? g dioxanone, and 0.01 g of catalyst '
(stannous octoate). This is a ratio of 21:1 D:PEG. Samples were also
made at other amounts of D ( 1.0 g, I 8:1; 0.84 g, 15 :1; I .34 g, 24:1 ).


CA 02396229 2002-08-22
44
Vials were sealed and heated at 150 for 5 hrs. Samples were dissolved in
chloroform; optionally precipitated in ether; and acrylated as described in
previous examples. NMR showed final molar ratios in the synthesized
polymer of D/PEG, 1.82; AclPEG, 1.64.
5 Macromer 35KDLA: To a mixd~re of 15 g PEG, 0.84 g
Dioxanone and 0.01 g catalyst was also added 0.39 g d,l-lactide. The
mixture was dried, then incubated at 185 ° overnight; dissolved in
chloroform and precipitated in ether, filtered and vacuum-dried; and
acrylated with excess acryloyl chloride and triethylamine.
10 In the following Examples 9-10, the following methods and
parameters were used. A person of skill in the art can also look to PCT
WO 96J29370 for other techniques that may be applicable.
E o~4g~tion to fracture and Youna's or other elastic modulus.
Samples are prepared in a mold to have the required concentration
15 of monomer and other ingredients. The crosslinked or otherwise cured
specimens are placed in an appropriate machine, such as an InstronTM
tester, and the force required to stretch the sample along a single axis is
measured as a function of the distance the sample is stretched (strain).
Elongation may be continued until the sample breaks, giving the value for
20 elongation at break, optionally after cycling at lower elongations to
determine the degree of any plastic deformation of the sample. The data
(force vs. distance) may be recorded and used to make a plot, as in Figure
3. Because the response of a particular material is not necessarily "ideal",
especially at high elongation, a modules may be calculated from values at
25 low degrees of elongation where the behavior is closer to linear.
Alternatively, the force vs. strain values may be used directly without
extrapolation, or without division by sample thickness to give the
"normalized compliance" discussed above.
Bulk CQpapression Modules.
30 The sample of gel or tissue is placed in a suitable instrument, such
as a Perkin-Elmer DMA 7e, and the modules is measured according to a


CA 02396229 2002-08-22
45
standard procedure. A gel sample could also be polymerized directly in
the instrument for testing.
Adhesive strey.
This was tested by a lap shear test. The test sealant material was
5 used to adhere a 1 cm x 1 cm area of two pieces of test substrate, typically
a standardized tissue such as rat peritoneum or pig pericardium. After
crosslinking or curing of the test material, the force required to break the
adhesive bond was determined using a suitable instrument, such as an
InstmnTM tester. In one variant of the test, three pieces of substrate were
10 adhered: a center piece, with tab extending in one direction, and a pair of
outer pieces with tabs extending in the opposite direction; sealant was used
to join all three pieces. Either arrangment also can be used to determine
the relative mechanical properties of various samples (i.e., compared to
standards) at small displacements, which is useful when only limited
15 sample volume is available.
A r
Adherence of sealant formulae in vivo is determined qualitatively,
by the relative resistance of the sealant to displacement from its deposition
site by a probe.
20 Visco '
Viscosity was measured by standard methods, typically in a
Brookfield'~'~" viscometer.
Seal Pressure Testing,
Seal Pressure Testing was performed by punching a 3 mm round
25 hole in a standard tissue, such as pig pericardium, and mounting the tissue
as the closure in a test fixture. Sealant was applied to the hole and cured,
typically in a spiral pattern, to obtain closure of the hole. Then
increasing pressure was applied to the transverse side of the tissue until the
plug of sealant was displaced.
30 Sealant Polymerization
In Examples 9-10 below, a preferred formulation of the sealing
system was used. When applied to tissue or to a surface to which


CA 02396229 2002-08-22
adherence was required, the surface was primed with a mixtiwe which
contained by weight approximately 65% water, 30.4% of a polymerizable
macromer (3.3KLSA2, a 3.5 kD polyethylene glycol backbone carrying an
average of 5 lactate groups and end capped with acrylate), 3% NaCI, 1%
5 fructose, 0.5% ferrous gluconate, and 0.2% Eosin Y. The primer was
applied to the surface and spread with a brush. Then about 2 volumes of
sealant solution was applied and mixed with a brush. The Sea>ant
contained about 77% water, 20.5% polymerizable macromer 35KTMC8A2
(35 kD polyethylene glycol carrying an average of 8 trimethylenecarbonate
10 groups and end capped with acrylate), 1.1 % triethanolamine, 1 %KH2P04,
0.4% vinylcaprolactam, 0.013% t-butyl hydroperoxide, and 0.002% Eosin
Y. When the sealant solution was tested in isolation, the t-butyl
hydropemxide was omitted. The sealant system was photopolymerized by
exposure to blue-green light for about 40 sec.
15 EXAMPLE 9. Elasticity Rauits.
Using the materials described above, lap shear testing samples were
prepared by applying the maeromer solution with a cotton swab to a 1 cm
X 1 cm area on a 3 cm X 1 cm strip of rat peritoneal tissue, then laying
the other strip of the same size on top as to make a sandwich. The sample
20 was then transilluminated from the top and then the bottom for 40 sec
each. Lap shear testing was performed using a 12.5 mm gauge length.
Tensile testing using a sample size of 45 mm X 10 mm X 5 mm and a
12.5 mm gauge length, was performed. DMA (Perkin Eliner) testing with
a sample height of 1.6 mm was performed at 3TC after hydrating for 2
25 hours in saline at 37'C. A subjective scoring system was used to assess
adherence in a goat lung model on a scale from 1-4 ( 1 = poor adherence
& 4 = excellent adherence).
I~ Vitro TcStIIIQ
This synthetic surgical sealant could be rapidly polymerized with
30 visible light to form a flexible hydrogel. As can be seen from the tensile
data in Figure 3, this material shovwed a completely elastic deformation
profile with linear elongation at break in excess of 700%. The


CA 02396229 2002-08-22
47
polymerization process of this material and the properties of lung tissue
and muscle tissue were studied using the dynamic mechanical tester. It
was seen that muscle tissue, as expected, had a higher modules than
spongy parenchyma) lung tissue. The sealant material was cured within ,40
5 seconds and reached a final modules very comparable to that of the lung
tissue. This ensures a compliant and persistent adhesive bond. The bond
strength was determined using the lap shear test app and the material
was sewn to form a strong yet flexible bond to tissue. This bond strength
is in excess of literature values for fibrin glues in comparable tests.
10 In Vivo Testine
All goats that had undergone the thoracotomy procedure survived
the surgery uneventfully. Goats were sacrificed at timepoints of I4 days,
1 month, and 3 months. At all timepoints, the hydrogel was seen to be
firm and clear and had an adherence score of 3.0-3.5 out of 4Ø No tissue
15 necrosis was evident. Histological sections of the tissue showed normal
healing. The results are shown below in Table 1.
Table 1: In-Vitro Testing Summary
Property; Result
Compressive modules at full cure, sealant; 32.4 kPa
Compressive modules of lung tissue, pig; 27.5
~ 3.4 kPa
Compressive modules of lung tissue, dog; 28.0
~ I .9 kPa
Modules of rat muscle tissue; 73.4 t 6.8 kPa
Youag's modules at full cure, sealant; 29.4 kPa
Elongation at break, sealant; 788 t 255.2
Sealant lap shear strength; 90.I7 t 18.17 glcm2


CA 02396229 2002-08-22
' ' 48
EXAMPLE 10. Comparative Results.
TissucolTM sealant is a commercial fibrin sealant used in Europe. It
is not at present approved for use in the United States, in part because it is
made from human serum and thus may carry infectious agents. Tissucol
sealant was used according to its manufacturer's directions. In comparison
to the preferred sealant formulation of the previous example, the
following results were obtained shown in Table 2:
Table 2: Properties of Sealaats
Test: . F~calSealT"~ i co '~'M
Sealant Sealant
A. Double lap shear 38 t6 kPa lOt 6 kPa
B. Compression Modules 32 ~ 1 kPa 35 ~ 5 kPa
C. Viscosity X780 cP at 20% 117 cP
conc. (fibrinogen)
1.6 CP
(thrombin)
D. Seal Pressure Test X380 ~ 100 X30
mm Hg t 20 mm Hg
When applied to a living dog lung, the fibrin sealant had an
adhesion score of 1, and leaked on all staple lines at 10-40 mm Hg. It
was difficult to apply the fibrin material to a punch-type leak, because air
bubbles coming through the leak tended to remove the material before it
polymerized. In contrast, sealant adhered to primed tissue with an
adhesion of 3.5, and typically withstood 80 mm Hg or more of presstu~e.
Its high viscosity slowed bubble penetration.
The optimal material for lung, as described above, has an
elongation at break of over 700°l0. Other materials were suitable, if
less
optimal. For non-collapsed lung, a araterial (20KT8A2) with an
elongation at break of 225% was suitable, while a material (8KLSA2)
with an elongation at break of 100% (and an elastic modules of 47 ~4


CA 02396229 2002-08-22
49
kPa) was not effective in lung. The expansion of a dog lung was
meas<urd. It was found that the effective area expansion during a normal
breathing cycle is about 200%, while the expansion from the atalectatic
(collapsed) state to full inflation changed area by about 300~/0. In the
5 latter case, an extension (strain) of about 100% was observed along one
axis, and about 200% along a perpendicular axis, implying non-uniformity
of the tissue structure.
Thus, an important requirement for a seaZaat system on this tissue
appears to be that the normalized compliance of the sealant is greater than
10 the normalized compliance of the tissue to which it is applial. While the
lung is perhaps the most dramatic example of tissue elasticity and area
expansion during normal physiological processes, other tissues, such as the
bowels, the bladder and large arteries, can change surface area
substantially during normal physiological cycles. Other tissues, such as the
15 beating heart, exhibit significant changes in shape (shear) without
necessarily changing local area.
The compliance of the sealant may be selected depending on the
tissue to which it is to be applied. A sealant having a high value of
normalized compliance, or a low value of the normalized compliance ratio
20 (tissue /material), may be beneficial for certain applications. For
example,
the 700% -elongation low-modulus material described above is also
suitable for sealing the dare of the brain, or the spinal cord after
laminectomy, even though these tissues are relatively non-compliant (i.e.,
are difficult to stretch). Thus, high normalized compliance sealant appears
25 to be useful on most tissues, and desirable as a material having a broad
range of applications.

Representative Drawing

Sorry, the representative drawing for patent document number 2396229 was not found.

Administrative Status

For a clearer understanding of the status of the application/patent presented on this page, the site Disclaimer , as well as the definitions for Patent , Administrative Status , Maintenance Fee  and Payment History  should be consulted.

Administrative Status

Title Date
Forecasted Issue Date 2006-05-30
(22) Filed 1997-09-23
(41) Open to Public Inspection 1998-03-26
Examination Requested 2002-08-22
(45) Issued 2006-05-30
Expired 2017-09-25

Abandonment History

There is no abandonment history.

Payment History

Fee Type Anniversary Year Due Date Amount Paid Paid Date
Request for Examination $400.00 2002-08-22
Registration of a document - section 124 $50.00 2002-08-22
Registration of a document - section 124 $50.00 2002-08-22
Registration of a document - section 124 $50.00 2002-08-22
Registration of a document - section 124 $50.00 2002-08-22
Registration of a document - section 124 $50.00 2002-08-22
Registration of a document - section 124 $50.00 2002-08-22
Registration of a document - section 124 $50.00 2002-08-22
Registration of a document - section 124 $50.00 2002-08-22
Registration of a document - section 124 $50.00 2002-08-22
Registration of a document - section 124 $50.00 2002-08-22
Registration of a document - section 124 $50.00 2002-08-22
Registration of a document - section 124 $50.00 2002-08-22
Application Fee $300.00 2002-08-22
Maintenance Fee - Application - New Act 2 1999-09-23 $100.00 2002-08-22
Maintenance Fee - Application - New Act 3 2000-09-25 $100.00 2002-08-22
Maintenance Fee - Application - New Act 4 2001-09-24 $100.00 2002-08-22
Maintenance Fee - Application - New Act 5 2002-09-23 $150.00 2002-08-22
Maintenance Fee - Application - New Act 6 2003-09-23 $150.00 2003-09-23
Maintenance Fee - Application - New Act 7 2004-09-23 $200.00 2004-09-09
Registration of a document - section 124 $100.00 2004-09-21
Maintenance Fee - Application - New Act 8 2005-09-23 $200.00 2005-09-08
Final Fee $300.00 2006-03-13
Maintenance Fee - Patent - New Act 9 2006-09-25 $200.00 2006-08-30
Maintenance Fee - Patent - New Act 10 2007-09-24 $250.00 2007-08-31
Maintenance Fee - Patent - New Act 11 2008-09-23 $250.00 2008-08-29
Maintenance Fee - Patent - New Act 12 2009-09-23 $250.00 2009-09-02
Maintenance Fee - Patent - New Act 13 2010-09-23 $250.00 2010-08-30
Maintenance Fee - Patent - New Act 14 2011-09-23 $250.00 2011-08-30
Maintenance Fee - Patent - New Act 15 2012-09-24 $450.00 2012-08-08
Maintenance Fee - Patent - New Act 16 2013-09-23 $450.00 2013-08-14
Maintenance Fee - Patent - New Act 17 2014-09-23 $450.00 2014-09-04
Maintenance Fee - Patent - New Act 18 2015-09-23 $450.00 2015-09-02
Maintenance Fee - Patent - New Act 19 2016-09-23 $450.00 2016-09-01
Owners on Record

Note: Records showing the ownership history in alphabetical order.

Current Owners on Record
GENZYME CORPORATION
Past Owners on Record
AVILA, LUIS Z.
BARMAN, SHIKHA P.
COURY, ARTHUR J.
ENSCORE, DAVID J.
FOCAL, INC.
GOODRICH, STEPHEN D.
JARRETT, PETER K.
NASON, WILLIAM C.
POWELL, MICHELLE D.
RUDOWSKY, RONALD S.
SAWHNEY, AMARPREET
WEAVER, DOUGLAS
YAO, FEI
Past Owners that do not appear in the "Owners on Record" listing will appear in other documentation within the application.
Documents

To view selected files, please enter reCAPTCHA code :



To view images, click a link in the Document Description column. To download the documents, select one or more checkboxes in the first column and then click the "Download Selected in PDF format (Zip Archive)" or the "Download Selected as Single PDF" button.

List of published and non-published patent-specific documents on the CPD .

If you have any difficulty accessing content, you can call the Client Service Centre at 1-866-997-1936 or send them an e-mail at CIPO Client Service Centre.


Document
Description 
Date
(yyyy-mm-dd) 
Number of pages   Size of Image (KB) 
Claims 2002-08-22 1 40
Cover Page 2006-05-10 2 42
Description 2003-01-31 50 2,382
Claims 2003-01-31 2 74
Description 2002-08-22 49 2,351
Abstract 2002-08-22 1 22
Cover Page 2002-10-31 2 49
Drawings 2002-08-22 2 29
Claims 2005-09-14 2 70
Fees 2004-09-09 1 37
Assignment 2004-09-21 5 163
Correspondence 2002-09-13 1 46
Assignment 2002-08-22 4 134
Correspondence 2002-10-17 1 18
Correspondence 2002-11-12 2 119
Correspondence 2003-01-10 1 46
Assignment 2003-01-16 1 37
Correspondence 2003-01-16 1 36
Prosecution-Amendment 2003-01-31 7 257
Correspondence 2003-05-05 1 16
Fees 2003-09-23 1 34
Prosecution-Amendment 2004-08-25 11 536
Prosecution-Amendment 2005-03-16 2 37
Fees 2005-09-08 1 31
Prosecution-Amendment 2005-09-14 2 68
Correspondence 2006-03-13 1 28